More than three years after Deciphera Pharmaceuticals’ first approval, the company appears to be on the precipice of achieving a second commercial product. Oral tumor treatment vimseltinib passed the ...

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) has recently experienced a daily loss of 2.19% and a 3-month loss of 10.22%. The company's Earnings Per Share (EPS) (EPS) also indicate a loss of 2.32.

Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) -Deciphera Pharmaceuticals said on Monday Japan's Ono Pharmaceutical Co will acquire the cancer drugmaker for $2.4 ...

Deciphera Pharmaceuticals has posted data from a phase 1 trial of its small molecule switch control inhibitor of CSF1R, DCC-3014. The early-phase data have emboldened Deciphera to expand the trial to ...

Long-established in the Drug Manufacturers industry, Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) has enjoyed a stellar reputation. However, it has recently witnessed a daily loss of 2.19%, juxtaposed ...

The late Steve Allen, creator of TV’s Tonight Show, song writer and musician, wrote the popular song “This Could Be The Start Of Something Big.” Today’s news story reporting Eli Lilly has entered into ...

Lawrence-based Deciphera Pharmaceuticals LLC is teaming up with Eli Lilly and Co. to license and develop technology designed to fight cancer, in a partnership announced Friday that ultimately could ...

Deciphera Pharmaceuticals, Inc. DCPH announced that the FDA has accepted the new drug application (NDA) for its investigational pipeline candidate ripretinib. The company is seeking approval of the ...

Deciphera Pharmaceuticals, Inc. DCPH announced that it has dosed the first patient in a phase I study which is evaluating its investigational ULK kinase inhibitor, DCC-3116, for the treatment of ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2022 financial results on Wednesday, May 4, 2022. In connection ...